Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. SCA Pharmaceuticals, Inc.
483
•SCA Pharmaceuticals, Inc.•November 7, 2019

SCA Pharmaceuticals, Inc. – FDA 483, Nov 7, 2019

Record Details

An FDA inspection of SCA Pharmaceuticals, Inc., an outsourcing facility located in Little Rock, AR, was conducted from October 28 to November 7, 2019. The inspection resulted in six observations detailed in a Form FDA 483, highlighting significant deficiencies related to drug manufacturing and quality control.

Key issues identified included inadequate sterility testing methods that did not meet USP <71> standards, and a failure to thoroughly investigate unexplained discrepancies, such as a confirmed potency failure for Vasopressin, without notifying customers of updated beyond-use dating. The company also lacked proper controls over computer systems, specifically failing to conduct audit trail reviews for sterility analysis software and allowing administrator access for routine tasks. Documentation for product examination was found to be insufficient, with reject products from visual inspections improperly segregated, leading to inaccurate batch records. Furthermore, SCA Pharmaceuticals was observed compounding drug products that are essentially copies of approved drugs, a violation of sections 503B(a)(5) and 503B(d)(2) of the Food, Drug, and Cosmetic Act. Lastly, employees performing sterility analysis lacked current training and recertification.

These observations indicate non-compliance with Current Good Manufacturing Practices (CGMP) and specific provisions for outsourcing facilities under the Drug Quality and Security Act. SCA Pharmaceuticals, Inc. is required to provide a comprehensive response detailing corrective and preventive actions to address each observation and ensure regulatory compliance.

Company
SCA Pharmaceuticals, Inc.
Inspection date
November 7, 2019
Product type
Drugs
Office
Dallas District Office
Person
  • Claire M. Minden (CO CDER OMQ)
View Company Profile

ID · d9de0613-d136-4442-8e3b-9a488253e118

Other documents for SCA Pharmaceuticals, Inc.
  • 483 - 2025-10-20October 20, 2025
  • 483 - 2023-05-17May 17, 2023
  • 483 - 2017-09-29September 29, 2017
  • 483 - 2014-04-01April 1, 2014

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore SCA Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.